-$0.53 EPS Expected for Epizyme Inc (EPZM) This Quarter

Wall Street analysts predict that Epizyme Inc (NASDAQ:EPZM) will report ($0.53) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Epizyme’s earnings, with the highest EPS estimate coming in at ($0.47) and the lowest estimate coming in at ($0.60). Epizyme reported earnings per share of ($0.48) in the same quarter last year, which suggests a negative year-over-year growth rate of 10.4%. The company is expected to announce its next quarterly earnings report on Friday, August 3rd.

According to Zacks, analysts expect that Epizyme will report full-year earnings of ($2.25) per share for the current year, with EPS estimates ranging from ($3.01) to ($1.85). For the next financial year, analysts expect that the company will post earnings of ($2.21) per share, with EPS estimates ranging from ($3.22) to ($0.74). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Epizyme.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.05. During the same period last year, the business earned ($0.56) earnings per share.

A number of analysts recently commented on the company. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a research report on Thursday, March 15th. BidaskClub upgraded Epizyme from a “hold” rating to a “buy” rating in a research report on Thursday, March 15th. Wedbush restated an “outperform” rating and set a $25.00 target price (down previously from $26.00) on shares of Epizyme in a report on Wednesday, March 14th. Leerink Swann raised their target price on Epizyme from $22.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, March 14th. Finally, SunTrust Banks restated a “buy” rating and set a $27.00 target price on shares of Epizyme in a report on Wednesday, March 14th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Epizyme currently has an average rating of “Buy” and a consensus target price of $22.92.

Institutional investors and hedge funds have recently modified their holdings of the business. Palo Alto Investors LP lifted its holdings in shares of Epizyme by 0.5% during the 1st quarter. Palo Alto Investors LP now owns 6,895,075 shares of the biopharmaceutical company’s stock valued at $122,388,000 after purchasing an additional 34,232 shares in the last quarter. Palo Alto Investors LLC lifted its holdings in shares of Epizyme by 7.2% during the 4th quarter. Palo Alto Investors LLC now owns 6,860,843 shares of the biopharmaceutical company’s stock valued at $86,104,000 after purchasing an additional 462,547 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Epizyme by 17.1% during the 4th quarter. BlackRock Inc. now owns 3,965,391 shares of the biopharmaceutical company’s stock valued at $49,766,000 after purchasing an additional 579,662 shares in the last quarter. Redmile Group LLC lifted its holdings in shares of Epizyme by 4.5% during the 1st quarter. Redmile Group LLC now owns 2,011,989 shares of the biopharmaceutical company’s stock valued at $35,713,000 after purchasing an additional 86,300 shares in the last quarter. Finally, Jennison Associates LLC lifted its holdings in shares of Epizyme by 0.4% during the 4th quarter. Jennison Associates LLC now owns 1,875,528 shares of the biopharmaceutical company’s stock valued at $23,538,000 after purchasing an additional 7,867 shares in the last quarter. Hedge funds and other institutional investors own 84.82% of the company’s stock.

EPZM stock traded up $0.05 during midday trading on Friday, reaching $18.45. The stock had a trading volume of 316,488 shares, compared to its average volume of 420,927. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -8.46 and a beta of 2.00. Epizyme has a twelve month low of $9.30 and a twelve month high of $21.40.

Epizyme Company Profile

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Get a free copy of the Zacks research report on Epizyme (EPZM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply